Ventyx Biosciences, Inc.
VTYX
$7.94
-$1.44-15.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.53% | -10.62% | -10.25% | -8.76% | -3.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.48% | -17.86% | -27.94% | -35.61% | -33.47% |
| Operating Income | 35.48% | 17.86% | 27.94% | 35.61% | 33.47% |
| Income Before Tax | 35.24% | 15.53% | 28.86% | 37.22% | 34.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.24% | 15.53% | 28.86% | 37.22% | 34.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.24% | 15.53% | 28.86% | 37.22% | 34.76% |
| EBIT | 35.48% | 17.86% | 27.94% | 35.61% | 33.47% |
| EBITDA | 35.52% | 17.88% | 28.06% | 35.66% | 33.55% |
| EPS Basic | 35.81% | 16.30% | 38.15% | 47.62% | 45.64% |
| Normalized Basic EPS | 35.82% | 16.29% | 38.16% | 47.61% | 45.63% |
| EPS Diluted | 35.81% | 16.30% | 38.15% | 47.62% | 45.64% |
| Normalized Diluted EPS | 35.82% | 16.29% | 38.16% | 47.61% | 45.63% |
| Average Basic Shares Outstanding | 0.90% | 0.91% | 15.04% | 19.86% | 20.02% |
| Average Diluted Shares Outstanding | 0.90% | 0.91% | 15.04% | 19.86% | 20.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |